

GLAXOSMITHKLINE PLC
Form 6-K
July 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 18 July 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain
 b) Position/status President, Global
 Pharmaceuticals

c) Initial notification/
 amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or
 auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be
 repeated for (i) each type of instrument; (ii) each
 type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Description of
 a) the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest
 in Ordinary Shares following
 the re-investment of
 dividends paid to
 shareholders on 14 July
 2016, on Ordinary Shares
 held in the Company's
 Deferred Investment Award
 Programme.

c) Price(s) and volume(s) Price(s) Volume(s)
 £16.4900 454.329
 n/a (single transaction)

d) Aggregated
 information
 Aggregated volume
 Price

e) Date of the transaction 2016-07-14

f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: July 18, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc